Mirataz is the first and only medication approved in the European Union to treat cats experiencing poor appetite and weight loss resulting from chronic medical conditions. San Francisco, California (December 12, 2019) – Kindred Biosciences, Inc. (Nasdaq: KIN), a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets, today announced that the […]
/wp-content/uploads/2017/09/KindredBioHeader2017.png00Katja Buhrer/wp-content/uploads/2017/09/KindredBioHeader2017.pngKatja Buhrer2019-12-12 09:09:292019-12-12 09:09:31Kindred Biosciences Announces European Commission Approval of Mirataz® 20 mg/g Transdermal Ointment for Cats Experiencing Poor Appetite and Weight Loss
San Francisco, California (November 25, 2019) – Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that the U.S. Food and Drug Administration’s Center for Veterinary Medicine has approved Zimeta™ (dipyrone injection) for the control of pyrexia in horses. Pyrexia, or fever, is associated with […]
/wp-content/uploads/2017/09/KindredBioHeader2017.png00Katja Buhrer/wp-content/uploads/2017/09/KindredBioHeader2017.pngKatja Buhrer2019-11-25 16:07:422019-11-25 16:07:44Kindred Biosciences Receives FDA Approval of Zimeta™ (dipyrone injection) for the Control of Pyrexia in Horses
San Francisco, California (November 14, 2019) – Kindred Biosciences, Inc. (NASDAQ: KIN), a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets, will participate in the Stifel Healthcare Conference on November 19 in New York City and Jefferies London Healthcare Conference on November 21. Dr. Richard Chin, Chief Executive Officer, will present and be available […]
/wp-content/uploads/2017/09/KindredBioHeader2017.png00Katja Buhrer/wp-content/uploads/2017/09/KindredBioHeader2017.pngKatja Buhrer2019-11-14 16:08:502019-11-14 16:08:51Kindred Biosciences to Participate in Stifel Healthcare Conference and Jefferies London Healthcare Conference
San Francisco, California (November 12, 2019) – Kindred Biosciences, Inc. (NASDAQ: KIN), a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets, today announced financial results for the third quarter ended September 30, 2019 and provided updates on its programs. For the third quarter 2019, KindredBio reported net product revenues of $1.1 million and a net loss […]
Company to Hold Conference Call and Webcast at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Time on Tuesday, November 12, 2019. San Francisco, California (October 28, 2019) — Kindred Biosciences, Inc. (NASDAQ: KIN), a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets, will release its third quarter 2019 financial results on November […]
0.00 (0.00%)
Kindred Biosciences Announces European Commission Approval of Mirataz® 20 mg/g Transdermal Ointment for Cats Experiencing Poor Appetite and Weight Loss
/in Frontpage, Investor, News /by Katja BuhrerMirataz is the first and only medication approved in the European Union to treat cats experiencing poor appetite and weight loss resulting from chronic medical conditions. San Francisco, California (December 12, 2019) – Kindred Biosciences, Inc. (Nasdaq: KIN), a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets, today announced that the […]
Kindred Biosciences Receives FDA Approval of Zimeta™ (dipyrone injection) for the Control of Pyrexia in Horses
/in Frontpage, Investor, News /by Katja BuhrerSan Francisco, California (November 25, 2019) – Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that the U.S. Food and Drug Administration’s Center for Veterinary Medicine has approved Zimeta™ (dipyrone injection) for the control of pyrexia in horses. Pyrexia, or fever, is associated with […]
Kindred Biosciences to Participate in Stifel Healthcare Conference and Jefferies London Healthcare Conference
/in Frontpage, Investor, News /by Katja BuhrerSan Francisco, California (November 14, 2019) – Kindred Biosciences, Inc. (NASDAQ: KIN), a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets, will participate in the Stifel Healthcare Conference on November 19 in New York City and Jefferies London Healthcare Conference on November 21. Dr. Richard Chin, Chief Executive Officer, will present and be available […]
Kindred Biosciences Announces Third Quarter 2019 Financial Results
/in Frontpage, Investor, News /by Katja BuhrerSan Francisco, California (November 12, 2019) – Kindred Biosciences, Inc. (NASDAQ: KIN), a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets, today announced financial results for the third quarter ended September 30, 2019 and provided updates on its programs. For the third quarter 2019, KindredBio reported net product revenues of $1.1 million and a net loss […]
Kindred Biosciences to Announce Third Quarter 2019 Financial Results
/in Frontpage, Investor, News /by Katja BuhrerCompany to Hold Conference Call and Webcast at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Time on Tuesday, November 12, 2019. San Francisco, California (October 28, 2019) — Kindred Biosciences, Inc. (NASDAQ: KIN), a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets, will release its third quarter 2019 financial results on November […]